3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
84
Thoracic
9
Breast
9
Dermatologic
6
Head & Neck
5
Genitourinary
5
Gastrointestinal
5
Sarcoma
4
Endocrine
3
Lymphoid
2
NET
1
Gynecologic
1
Conditions
Neuroendocrine Tumors
28
Neoplasms
4
Melanoma
4
Carcinoma, Neuroendocrine
4
Sarcoma
3
Pheochromocytoma
3
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Liver Neoplasms
3
Gastro-enteropancreatic neuroendocrine tumor
3
Colonic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma
3
Carcinoid Tumor
3
Breast Neoplasms
3
Thyroid Neoplasms
2
Thymus Neoplasms
2
Stomach Neoplasms
2
Salivary Gland Neoplasms
2
Rectal Neoplasms
2
Prostatic Neoplasms
2
Paraganglioma
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Meningioma
2
Lung Neoplasms
2
Insulinoma
2
Head and Neck Neoplasms
2
Interventions
entrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
NET
×
30 days
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA